Jorge Conde

1. Key Themes

mRNA as an Information Platform, Not Just a Drug

The fundamental insight is that mRNA is an information molecule — Moderna receives a digital file of tumor sequences and healthy cell sequences, then synthesizes medicine entirely from that data. This is what makes personalization at scale possible in a way that protein or peptide-based approaches never could be.

"The beautiful thing of mRNA — it's an information molecule. And so basically what we get from the lab is the sequence of your healthy cells and the sequence of your cancer cells, so we just get a file and then we use that information to basically make the DNA." 00:21:27

Personalization Is Not Optional — It Is Mechanistically Required

When Moderna started, they genuinely didn't know what percentage of antigens would overlap across patients. The answer — 90% are unique — proves that a shared-antigen approach was never going to work for this cancer type.

"Around 90% of the antigen are different from a human to another one. Because when we started, we had no idea... we were like, we have no idea if we're going to get 2%, 5%, 90% of the same antigen across all the patients. Actually, 90% of the antigen are different from a human to another one." 00:14:51

Keytruda Alone Has a 40% Failure Rate — A Massive Unmet Need Moderna Is Targeting

Checkpoint inhibitors like Keytruda are considered among the most successful cancer drugs ever, yet 4 in 10 patients don't respond — and those non-responders still suffer serious autoimmune side effects. This is the gap Moderna's mRNA vaccine is designed to close.

"Only 60% of people are disease-free after five years... it means that there's 40% of people where you go through the treatment, you're fighting for cancer, and the treatment doesn't really work for you. And also... a lot of times come with very serious side effects... people that get checkpoints... they end up having type 1 diabetes, lupus, Crohn disease." 00:07:32

The Phase Three Result Is a Historic First in Oncology Vaccine History

Over 1,000 cancer vaccine clinical trials have failed over 20+ years. This is the first success — and it also hit a secondary endpoint (distant metastasis-free survival) that was not expected at the first interim analysis.

"It's the first time there is a cancer vaccine working. The field has been doing that for 20 plus years, more than a thousand clinical trials that have all failed." 00:00:00

"To our own surprise... we met the secondary endpoint, which was distant metastasis-free survival... unexpected from our side, but again, means it is really good." 00:04:31

The Algorithm Is Version 1.0 — The Best Results Are Still Ahead

The phase three used a 10-year-old algorithm frozen in time. Moderna now has access to phase three patient blood and sequence data and intends to mine it to improve antigen selection. Stefan explicitly frames this the way AI improvement is framed.

"The current version of Intismeran that Moderna is the worst version of Intismeran you're going to see for the rest of medical history. And so that gave me a lot of hope not only in melanoma for those 20% of patients that don't respond but also for potentially other tumors that have been really hard in the field like pancreas cancer." 00:17:36

Operational Obsession: Square Inches and Cycle Time Are the Variables That Determine Cost

Stefan frames manufacturing efficiency in two explicit dimensions — cycle time (needle to needle) and floor space (square inches in a clean room). Both directly determine cost of goods and scalability. This is engineering discipline applied to biology.

"I'm always a pain about... all the space we can save, how we can be creative, how even we can move some compute out of the clean rooms just to shrink things as much as you can, because it has a huge impact on cost of the product at the end of the day." 00:24:22

The Regulatory Pathway Is Process BLA, Not Product BLA — A Critical Precedent

Personalized medicine cannot be approved product by product. CAR-T established the model, and Moderna has been building toward a process IND/BLA framework for a decade through continuous FDA engagement — not as a last step but throughout the trial.

"The whole process since we started in the clinic, the IND was a process IND... it's not like we have not talked to FDA for the last 10 years and we are going to show up at their front door in a week or two... there's been a lot of discussion." 00:28:11

Expansion Roadmap: Three Vectors Beyond Melanoma

Stefan articulates a precise three-vector expansion: (1) where Keytruda works — add Intismeran on top; (2) early-stage disease where checkpoints aren't used due to side effects — Intismeran monotherapy; (3) cancers where checkpoints fail entirely, like pancreatic and gastric cancer.

"Three different vectors we're going after in terms of expansion from melanoma... we're in phase 3 for lung, we're in phase 2 for kidney cancer, bladder cancer... the second vector is to go early in disease where checkpoint work... the third vector is where checkpoint don't work — so of course it's where you have the highest risk... two places we're trying right now is pancreas cancer and also gastric cancer." 00:30:57

mRNA Platform Has Three Distinct Disease Verticals Beyond Cancer

Moderna is simultaneously pointing the same platform at rare genetic diseases of the liver in children (pivotal data expected before year-end 2026) and autoimmune disease — including an individualized autoimmune treatment targeting specific misbehaving immune cells.

"Before the end of the year we should have our pivotal study for rare genetic disease for kids that have rare genetic disease of the liver... And in June we had our annual science day and we announced that the next mountain where we're pointing on mRNA platform is autoimmune disease." 00:36:53

2. Contrarian Perspectives

Cancer Vaccines Have Always Failed — Until Now, and the Reason Is Counterintuitive

The conventional wisdom was that the immune system simply couldn't be retrained against cancer. The contrarian truth is that it can be — but only if you go fully individualized. Every prior attempt used shared antigens, which was mechanistically wrong given that 90% of tumor antigens are unique to each patient.

"In the past, a lot of times people have tried with non-mRNA, i.e. protein technology or peptide, but also we tried a shared antigen. Whereas here what we said is... we're going to literally compare letter by letter, nucleotide by nucleotide." 00:13:27

DIY Personalized Medicine Will Not Compete With Industrial Personalized Medicine

The GitLab founder's DIY cancer vaccine made headlines, but Stefan's view is that industrial GMP manufacturing is not just preferable — it's a safety and quality question. When industrial options exist, doing it yourself introduces contamination and process risk.

"I think they will come most of them to Moderna because it will just be easier and safer... if you inject to somebody a product that has even one copier bacteria you might give the patient sepsis... it's a bit like every tool in life — when you have a store making high quality knives down the street you're going to use your time to do something else." 00:26:30

mRNA's Advantage Is Internal Presentation, Not Just Delivery Speed

The field often credits mRNA's COVID success to speed of manufacture. Stefan argues the deeper immunological advantage is where and how antigens are presented — from within the antigen-presenting cell itself, not circulating in the blood as proteins do. This is what prior cancer vaccine attempts missed.

"We think it's a very important differentiation from most of the previous vaccine in cancer in the field that were made by protein or peptide... recombinant or protein, when you inject them, they just go into your blood and they turn around. So your immune system sees them, but not in the same manner from within as it's done with the mRNA." 00:12:59

Stage 1 Cancer Patients Should Be Vaccinated Without Checkpoint Inhibitors — Not Watched

The current standard of care for early-stage lung cancer is surveillance, because checkpoint inhibitors cause permanent autoimmune side effects that aren't worth the risk at stage 1. The contrarian bet is that Intismeran monotherapy — with side effects comparable to a flu shot — changes the risk-benefit calculus entirely.

"What if you could have an mRNA made for cancer patient that has lung disease stage 1... the side effect is similar to a vaccine, you might feel tired for a day but that's it, so in cancer it's a pretty cool type of side effect right." 00:32:56

3. Companies Identified

Moderna

Biotechnology company pioneering mRNA medicines. Central subject of the episode — announced positive phase three results for Intismeran, a personalized mRNA cancer vaccine for melanoma, in August 2026, showing ~80% of patients disease-free at five years versus ~60% on Keytruda alone. Also advancing into lung, kidney, bladder, pancreatic, and gastric cancers, rare genetic liver diseases in children, and autoimmune disease.

"After working 10 years on an individualized treatment against cancer using mRNA technology, the phase three was positive... it's the first time that there is an agent in melanoma that is better than Keytruda alone." 00:04:03

Merck

Global pharmaceutical company, partner with Moderna on Intismeran. Makes Keytruda (pembrolizumab), the leading PD-1 checkpoint inhibitor. Jointly announced the phase three results and is co-developing the cancer vaccine program.

"We are working very hard already with regulators to file so that the drug can be available to patients as soon as possible... in 2027." 00:06:19

Revolution Medicine

Oncology drug company. Received approval for a KRAS-targeting medicine for pancreatic cancer the day before recording. Stefan explicitly identifies combination with Intismeran as a scientifically compelling next step.

"Literally yesterday, Revolution Medicine had a wonderful new medicine approved for pancreas cancer using the KRAS mutation. What if you could combine that medicine and Intismeran — those are very orthogonal mechanism of action." 00:34:29

Karolinska Institute

Swedish research institute — Nobel Prize awarding body. Moderna's published research partner demonstrating that their mRNA technology delivers antigen presentation from within antigen-presenting cells (APCs), which is the mechanistic basis of why the cancer vaccine works.

"We have known and published, actually with Karolinska... that with our technology, when we inject our mRNA in a muscle... basically the mRNA goes down to your lymph node and enters the APCs, the antigen-presenting cell... and the mRNA gets inside the APCs." 00:12:02

4. People Identified

Stefan Bancel

CEO of Moderna. Engineer by background and training, obsessed with manufacturing process, cycle time, and square-inch efficiency. Led Moderna from early mRNA infectious disease work through COVID vaccine to the first successful personalized cancer vaccine. Has been working on this cancer program for a decade.

"You are well — first of all you are an engineer at heart, and you have from the very very beginning been obsessed with process, with operations, with being efficient, and those things need to be absolutely true if you're going to attempt to do what you're trying to do here with personalized cancer vaccines." 00:18:54

General partner at a16z on the Bio & Health team. Has known Stefan Bancel since Moderna's earliest days. Former bioinformatics and genomics executive; deeply fluent in oncology biology, immunology, and drug development. Host of the interview.

"I'm Jorge Conde, a general partner on the A16Z Bio and Health team." 00:02:20

5. Operating Insights

Deliberately Underbuild for Quality First, Optimize for Efficiency Only After Clinical Validation

Moderna intentionally built a first-generation manufacturing robot that was quality-assured but operationally inefficient. They made this choice explicitly to avoid confounding a clinical failure with a manufacturing failure — only after proof of clinical efficacy did they dedicate top engineering talent to optimization.

"We told the team: make it good enough so you have good quality, but we're not serving for efficiencies yet. Because if it doesn't work in a clinic, what's the point of wasting five years making a beautiful, amazing, optimized robot if science doesn't work?... You run the study and it tells you the science doesn't work, and you don't... if it should have worked right, that would be a disaster for humanity." 00:22:25

Phase Three Clinical Data Is Also the R&D Dataset for Version 2.0

Moderna treats its own phase three patient blood samples and sequences as a proprietary AI/ML training dataset. The clinical trial is not just a regulatory gate — it is the data generation event that fuels the next algorithmic iteration.

"One other thing we're going to be doing now that we have access to phase three patient data and samples is to go back and mine that data to figure out why some patient responded and why some other patients did not respond... and we will go to see FDA if we find scientific reason why we should change the algorithm to go from 1.0 to a 2.0 algorithm." 00:17:06

Fix Cost Per Unit by Obsessing Over Clean Room Footprint, Not Just Throughput

Stefan's manufacturing insight is that in regulated clean room environments, floor space is the binding constraint. Reducing the footprint of each machine is equivalent to adding capacity for free. Moving compute hardware outside the clean room is one specific tactic mentioned.

"One way to reduce the cost is reduce the footprint on the floor. Because if you have a fixed envelope of a clean room facility and you can put 2x or 10x more machines in that surface area, of course you're going to get a bigger throughput and a much lower price on your fixed cost." 00:23:53

6. Overlooked Insights

Synthetic Enzymatic Manufacturing Is a Fundamental Process Shift That Makes Personalized Medicine Economics Possible

Stefan briefly draws a distinction that most listeners would miss entirely: Moderna no longer uses plasmid-grown E. coli to make the DNA template. Everything is synthetic, enzymatic, done in water. This makes the process fundamentally more like small molecule manufacturing than biologics — tiny reactors, no living cells, no large volumes. This is the silent reason why one-patient-at-a-time manufacturing is even economically conceivable, and it represents a manufacturing paradigm shift that has implications far beyond cancer vaccines.

"We make it all synthetic, so it's all enzymatic in liquid, in water. Then we make the RNA from the template, then we put the lipid around it. And because of that, and that it's a synthetic process, it's much more like small molecule than large molecule... the reactors are very, very tiny." 00:21:27

Individualized Autoimmune Disease Treatment — Targeting the Specific Misbehaving Immune Cells

Stefan mentions this almost in passing as a lab-stage program, but the concept is strikingly novel and barely gets airtime: an individualized mRNA treatment for autoimmune disease that doesn't just suppress the immune system broadly (as all current autoimmune drugs do) but specifically identifies and eliminates only the immune cells that are attacking self-tissue. If this works, it would be the first mechanism to actually resolve autoimmune disease rather than manage it — a market dwarfing oncology.

"What I'm most excited about, which is in the lab still, is the ability to do individualized autoimmune treatment where you target directly to the immune cells that are attacking your body as self when you have an autoimmune disease, and to basically... take the symptom of the immune disease out." 00:38:10